| Project/Area Number |
15K07963
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pharmacology in pharmacy
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
OBARA Yutaro 山形大学, 医学部, 准教授 (40400270)
|
|---|
| Research Collaborator |
STORK Philip
HABECKER Beth
NAKAGAWASAI Osamu
ICHIYANAGI Osamu
|
|---|
| Project Period (FY) |
2015-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 神経栄養因子 / NGF / ERK5 / MAPK / カテコラミン / チロシンヒドロキシラーゼ / ankrd1 / midnolin / 褐色細胞腫 / パーキンソン病 / 神経細胞 / 副腎髄質 |
|---|
| Outline of Final Research Achievements |
ERK5 is a member of MAPK family and involved in neurite outgrowth and biosynthesis of catecholamines including dopamine and noradrenalin. In the present study, we found that ERK5 promotes gene expression of ankrd1, MIDN and Kv4.2 during differentiation towards mature neurons, causing neurite outgrowth, catecholamine biosynthesis and increase in membrane excitability. These results suggest that disruption of this ERK5 signaling results in development and progress of Parkinson's disease and adrenal pheochromocytoma.
|
| Academic Significance and Societal Importance of the Research Achievements |
これまでにERK5の神経機能の調節機構はほとんど不明であったが、本研究によりin vitro、in vivoさらには臨床面でのERK5のカテコラミン生合成に対する役割が明らかになった。これは独創的な研究結果であり、学術的に意義が大きいと思われる。さらにERK5は、カテコラミンと関連する高血圧症や中枢神経疾患の治療を目指した創薬の標的であり、ERK5を利用した新しいタイプの分子標的薬の開発が期待されることが社会的な意義である。
|
